Skip to main content
SpringerLink
Log in

Infigratinib-related adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhao D, et al. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System. Drugs in R and D : 12 Sep 2023. Available from: URL: http://doi.org/10.1007/s40268-023-00439-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Infigratinib-related adverse events. Reactions Weekly 1975, 11 (2023). https://doi.org/10.1007/s40278-023-46366-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-46366-5

Search

Navigation